Executive Summary
Capacity is the visible half
The biomedical manufacturing cluster grew 16.2% year on year across the first ten months of 2025, with the pharmaceuticals segment up 122.9% in October alone on higher active-ingredient and biological output [EDB Mfg 2025]. Against a base of S$38.1 bn in 2023 [EDB BMS 2023], we put 2025 output near S$43 bn and 2027 near S$49 bn [Kira estimates]. Disclosed additions alone bring 144,000 litres of drug-substance capacity on line between 2024 and 2027 [WuXi Bio 2026] [AbbVie 2024].
Origination is the harder half
The national drug-discovery platform has executed close to 20 licensing deals across 25 corporate partners and more than 70 academic institutions [EDDC AR 2025]. We count eight Singapore-origin out-licensing transactions in 2025 against three in 2022 [Kira estimates] — genuine momentum, set against US$135.7 bn of Chinese out-licensing value in the same year [China Lic 2026].
A narrow base, carrying a wide share of the economy
Biomedical output is concentrated in a handful of plants on one estate, yet it carries roughly a fifth of manufacturing value-added and the fifth-largest export line. Concentration cuts both ways — it delivers scale economics and it transmits any single policy shock straight through.
Weight out of proportion to footprint
Biomedical manufacturing generated S$38.1 bn of output in 2023 and supplied about 22% of total manufacturing value-added [EDB BMS 2023], on roughly 2.6% of gross domestic product [EDB BMS 2023]. Pharmaceutical products were the fifth-largest export line in 2024 at US$15.5 bn, ranking Singapore sixteenth among exporters worldwide [OEC Trade 2024].
The mix is tilting to biologics
We split the 2023 cluster at roughly S$27.0 bn pharmaceuticals and biologics against S$11.1 bn medical technology, moving to S$36.5 bn and S$12.5 bn by 2027 [Kira estimates]. The growth is disproportionately biologic: the October 2025 print showed the pharmaceuticals segment up 122.9% on higher active-ingredient and biological production [EDB Mfg 2025].
Commitment has not slowed
Investment commitments in 2025 reached S$14.2 bn of fixed assets, of which manufacturing took about S$12.1 bn, alongside S$8.9 bn of annual business spending and 15,700 jobs [EDB Review 2025]. Four companies joined the precision-medicine pre-competitive consortium in the same year [EDB Review 2025].